NOVO NORDISK STOCK IS CRASHING!
8:40In this video, we analyze the significant decline of Novo Nordisk's stock, which has dropped over 57% in the past year, including a recent 7.81% fall due to disappointing trial results for its Alzheimer's drug. We explore the competitive landscape with Eli Lilly, the implications of lowered guidance, and the potential for recovery amidst investor uncertainty.



































